Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Geovax Labs

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of immunotherapies and vaccines against cancers and infectious diseases using a novel vector vaccine platform. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus (HIV), as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GeoVax Labs advances cancer therapies and COVID-19 vaccine development

GeoVax Labs showcased advancements in cancer therapies and COVID-19 vaccine development, underlining a commitment to innovation and global healthcare improvement.
While facing financial challenges due to increased R&D expenses and net loss, GeoVax's strategic strengths in vaccine development and clinical trials offer promising opportunities for growth.
The completion of the Gedeptin trial, ongoing Phase II trials for CM04S1, and plans for future vaccine developments position GeoVax for impactful contributions to healthcare.

GeoVax Labs reports Q2 loss, progresses in key trials

GeoVax's Q2 performance reflects ongoing investment in R&D and progress in key clinical trials.
The company's strengths lie in securing funding, commitment to innovation, and vaccine differentiation.
Challenges include recruitment issues, funding needs, and uncertainties in the pipeline.
Opportunities exist in fundraising, vaccine development, expanding indications, and optimizing clinical trials.

GeoVax Labs reports Q3 progress with vaccine trials and financial challenges

GeoVax Labs' Q3 performance reflects a mix of achievements and challenges, with a focus on advancing vaccine candidates and managing financials. The company's strengths in innovation and clinical trial strategies position it well for future growth opportunities through partnerships and regulatory advancements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GeoVax Labs, Inc. is a clinical-stage biotechnology company, which engages in the development of human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. It focuses on preventive vaccines against hemorrhagic fever viruses such as Ebola, Sudan, Marburg, and Lassa fever, the Zika virus and malaria, and human immunodeficiency virus, as well as immunotherapies for solid tumor cancers. The company was founded in June 1988 and is headquartered in Smyrna, GA.

Missfresh Ltd

View

Here's what you need to know about trading penny stocks on June 2nd The post What to Know About Buying Penny Stocks on June 2nd appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What to Know About Buying Penny Stocks on June 2nd

Aethlon Medical

Chimerix

Monkeypox penny stocks to watch right now The post Top Penny Stocks To Watch As Monkeypox Cases Rise appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks To Watch As Monkeypox Cases Rise

Endo International

FuelCell Energy

Here are three penny stocks to watch after today's bullish session The post Top Penny Stocks to Watch After a Bullish Trading Day  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Watch After a Bullish Trading Day

Atlanta, GA, May 25, 2022 (GLOBE NEWSWIRE) -- via  NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of 3,030,304 shares of common stock at a purchase price of $1.65 per share (or pre-funded warrant in lieu thereof) in a registered direct offering priced at a premium to market under Nasdaq rules. In a concurrent private placement, GeoVax has also agreed to issue and sell to the investor 9,090,910 shares of common stock (or common stock equivalents) at the same purchase price as in the registered direct offering.  In addition, the Company has agreed to issue to the investor in the offerings unregistered preferred investment options (the “investment options”) to purchase up to an aggregate of 12,121,214 shares of common stock.  The aggregate gross proceeds to the Company of both offerings are expected to be approximately $20 million.  The offerings are expected to close on or about May 27, 2022, subject to the satisfaction of customary closing conditions.

GeoVax Announces $20 Million Registered Direct and PIPE Offerings Priced at a Premium to Market Under Nasdaq Rules

Didi Global

SciSparc Ltd

Are these penny stocks on your list right now? The post 3 Penny Stocks Worth Watching This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks Worth Watching This Week

Emergent BioSolutions

Inovio Pharmaceuticals

SIGA Technologies

Tonix Pharmaceuticals Hld

Wondering what are the best monkeypox stocks to watch? Here are the companies producing vaccines to help fight the spread of the virus.

7 Monkeypox Stocks to Watch Right Now

Atlanta, GA, May 24, 2022 (GLOBE NEWSWIRE) -- IND-Enabling Studies Underway in the United States for MVA-VLP-MUC1 Vaccine Candidate

GeoVax Receives Notice of Allowance for Cancer Vaccine Patent in China

Foresight Autonomous Hlds

Safe Bulkers

Check these three penny stocks for your watchlist The post Top Penny Stocks to Buy Now? 3 to Watch as May Ends  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks to Buy Now? 3 to Watch as May Ends

GOVX stock is jumping on the firm's 2020 statement that the "basis" of its vaccine vector was approved as for monkeypox prevention. The post Why Is GeoVax (GOVX) Stock Up 25% Today?

Why Is GeoVax (GOVX) Stock Up 25% Today?

Monkeypox stocks to watch today. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? Hot Monkeypox Stocks To Watch Today

ATLANTA, GA, May 04, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today that it will be represented during presentations at the following upcoming scientific conferences.

GeoVax Announces Upcoming Presentations at Scientific Conferences

GeoVax Labs, Inc (NASDAQ:GOVX ) Q1 2022 Earnings Conference Call April 27, 2022 4:30 PM ET Company Participants David A. Dodd – Chairman and Chief Executive Officer Mark Reynolds – Chief Financial Officer Mark Newman – Chief Scientific Officer John W.

GeoVax Labs, Inc (GOVX) CEO David A. Dodd on Q1 2022 Results - Earnings Call Transcript - Earnings Call Transcript

Company Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology

GeoVax Reports 2022 First Quarter Financial Results and Provides Corporate Update

Camber Energy

Evoke Pharma

Why these 3 penny stocks are climbing today The post 3 Hot Penny Stocks to Watch as EVOK Stock Climbs 120% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks to Watch as EVOK Stock Climbs 120%

The U.S. Patent and Trademark Office has issued Patent No. 11,311,612 covering GeoVax Labs Inc's (NASDAQ: GOVX) modified vaccinia Ankara (MVA) vector expressing certain antigens from the malaria parasite.

GeoVax Labs Stock Jumps On US Patent For Malaria Vaccine Candidate

Conference call to be held Wednesday, April 27, at 4:30 p.m. Eastern Time

GeoVax to Report First Quarter 2022 Financial Results on Wednesday, April 27, 2022 and Provide Corporate Update

Company's COVID-19 Vaccine Candidate GEO-CM04S1 Continues to Advance in COVID-19 Phase 2 Clinical Trials While the Experimental Universal Vaccine Candidate GEO-CM02 Demonstrated Single-Dose, 100% Protection in Lethal Animal Challenge Model

GeoVax to Participate in Expert Panel Discussion on Pan-Corona and Universal Vaccines at the World Vaccine Congress

IND-Enabling Studies Underway for MVA-VLP-MUC1 Vaccine Candidate

GeoVax Announces Issuance of Cancer Vaccine Patent

Presentation to Focus on GEO-CM02 Being Developed as a Universal Vaccine to Address Evolving SARS-CoV-2 Variants

GeoVax to Present COVID-19 Vaccine Data at the Vaccine Summit Boston 2022

ATLANTA, GA, March 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the engagement of

GeoVax Retains CATO SMS to Manage Two Phase 2 COVID-19 Vaccine Clinical Trials

The investigational vaccine is now being used in Phase 2 trials for immunocompromised patients and as a booster for healthy adult volunteers

Data Published in a Lancet Journal on COH04S1, a City of Hope-Developed COVID-19 Vaccine, Shows it Produced Robust Antibodies and T cells Against SARS-CoV-2

GeoVax Labs, Inc. (GOVX) CEO David Dodd on Q4 2021 Results - Earnings Call Transcript

Advancing Phase 2 Clinical Trials for COVID-19 and Immuno-Oncology

GeoVax Reports 2021 Year-End Financial Results and Provides Corporate Update

Operational Resources Strengthened in Support of Ongoing Phase 2 Clinical Trials for COVID-19 and Advanced Head & Neck Cancer

GeoVax Announces Key Staff Appointments

Conference call to be held Wednesday, March 9, at 4:30 p.m. Eastern Time

News for Geovax Labs Stock (GOVX)